Zenuzolac is under clinical development by Inovio Pharmaceuticals and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zenuzolac’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zenuzolac (VGX-1027) is under development for the treatment of severe pneumonitis caused by Coronavirus Disease 2019 (COVID-19), inflammatory diseases and diabetic nephropathy. The drug candidate is administered through oral route. It acts by targeting pro-inflammatory responses including TNF-alpha, NF-kB and P38 MAP kinase signaling pathways.
It was also under development for the treatment of rheumatoid arthritis (RA), type 1 diabetes (T1D), Crohn's disease, uveitis and colitis.
Inovio Pharmaceuticals overview
Inovio Pharmaceuticals (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; INO-3107 for recurrent respiratory papillomatosis (RRP); and INO-5151 for prostate cancer. The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
For a complete picture of Zenuzolac’s drug-specific PTSR and LoA scores, buy the report here.